|
Easy method to make antibody-drug conjugates that target specific sites
Can be used to kill HER2-expressing breast cancer cells
May be used to deliver drugs for other purposes
Abstract
Researchers at USC developed an innovative class of site-specific ADCs that can be generated in just a single step by coupling proprietary bifunctional antibody...
|
|
Improves the efficacy of current immunotherapies by individually targeting T cell receptors proteins
Creates a therapy that boasts a higher chance of survival compared to the standard of care for acute myeloid leukemia
Abstract
USC researchers created genetically engineered exosomes (SMART-Exos) that display two distinct monoclonal antibodies targeting...
|
|
Deliver drugs for cancer and other diseases
Abstract
Using a newly discovered NAD+ analogue with excellent activity for poly-ADP-ribosylation, functionalized poly-ADP-ribose polymers were robustly synthesized. The functionalized poly-ADP-ribose polymers provide a novel type of drug carrier that allows for facile conjugation of monoclonal antibodies...
|
|
Targeted cancer immunotherapy
Biomedical research
Pharmacological innovation
Abstract
USC researchers have developed a novel approach using PAR polymers for the synthesis of bispecific antibodies, targeting both HER2 and T-cell CD3 antigens. By conjugating anti-HER2 and anti-CD3 monoclonal antibodies to azido-functionalized PAR polymers, researchers...
|
|
Therapeutic delivery
Biomedical research
Drug development
Abstract
USC researchers have generated PAR polymers with high therapeutic potential. They synthesized PAR polymers conjugated with human granulocyte colony-stimulating factor (GCSF) protein using auto-poly- ADP-ribosylation. The resulting PAR polymer-based conjugate, with multivalent GCSF...
|